Asia Healthcare Holdings is planning for a possible public listing over the coming year to year-and-a-half, though it will wait for a more favourable market environment before committing to an initial public offering, Executive Chairman Vishal Bali said.
Backed by Singapore sovereign investor GIC and private equity firm TPG, AHH has invested in excess of $300 million across healthcare businesses during the last decade. Bali told Reuters the group is monitoring market dynamics closely and that market calm is a prerequisite for proceeding.
"We believe an IPO is the right trajectory for AHH over the next year to 18 months, but it all depends on the market stability," Bali said. He added a blunt warning about current conditions: "With the current bloodbath, one should not even think about it."
AHH focuses on investing in and scaling single-specialty healthcare platforms. Management is evaluating further expansion into gastroenterology and pathology diagnostics as part of the next phase of growth. The interest in pathology diagnostics is informed by volumes generated within the company’s hospitals - Bali noted AHH currently books roughly 400 million rupees, or about $4.20 million, of pathology work.
Over the years the firm has acquired and grown several specialist healthcare providers, including Motherhood Hospitals, Nova IVF, and the Asian Institute of Nephrology and Urology. AHH intends to extend services offered by these assets into Tier-2 and Tier-3 cities as part of its expansion plans.
Bali also said the firm is not contemplating individual exits from its portfolio companies and does not require fresh capital at present. The company could allocate up to $150 million in new investments over the next two years, but will do so selectively and only when it identifies a clear new vertical to pursue.
Context and next steps
AHH’s timetable for an IPO remains conditional on market stability. In the meantime the group will continue to deploy capital selectively into areas aligned with existing hospital volumes and single-specialty strategies, while keeping portfolio companies intact rather than pursuing piecemeal sales.